TrialLeukemia2023

A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.

Christine E Ryan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.